Back to Directory
Bigespas
Founded 2020
Small-molecule drug development for Alzheimer’s disease
Bigespas is a biopharmaceutical company developing a small-molecule treatment for Alzheimer’s disease. Its lead candidate, DMB-I, is a crystalline form of latrepirdine, a compound previously investigated under the name Dimebon. Bigespas holds a US patent covering the polymorph and funded a Phase II study in people with mild to moderate Alzheimer’s dementia. Results from the randomised, double-blind study were published in 2026.